NASDAQ:APLT - Applied Therapeutics Stock Price, Forecast & News

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

Applied Therapeutics (NASDAQ:APLT) announced its earnings results on Wednesday, November, 13th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.14. View Applied Therapeutics' Earnings History.

Applied Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Applied Therapeutics.

4 Wall Street analysts have issued 12 month price targets for Applied Therapeutics' stock. Their forecasts range from $24.00 to $29.00. On average, they anticipate Applied Therapeutics' share price to reach $26.50 in the next year. This suggests a possible upside of 26.6% from the stock's current price. View Analyst Price Targets for Applied Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Therapeutics.

Media stories about APLT stock have been trending negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Applied Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Applied Therapeutics.

Applied Therapeutics saw a decrease in short interest in the month of November. As of November 29th, there was short interest totalling 105,000 shares, a decrease of 9.5% from the November 14th total of 116,000 shares. Based on an average daily volume of 35,900 shares, the days-to-cover ratio is currently 2.9 days. Approximately 1.4% of the company's shares are short sold. View Applied Therapeutics' Current Options Chain.

Some companies that are related to Applied Therapeutics include Nabriva Therapeutics (NBRV), Esperion Therapeutics (ESPR), Y-mAbs Therapeutics (YMAB), Innoviva (INVA), Athenex (ATNX), Arvinas (ARVN), Enanta Pharmaceuticals (ENTA), NextCure (NXTC), Principia Biopharma (PRNB), Constellation Pharmaceuticals (CNST), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Spectrum Pharmaceuticals (SPPI), Supernus Pharmaceuticals (SUPN) and ArQule (ARQL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Allena Pharmaceuticals (ALNA), eHealth (EHTH), Iovance Biotherapeutics (IOVA), Pinterest (PINS), ADMA Biologics (ADMA), Aeglea Bio Therapeutics (AGLE), Aqua Metals (AQMS), CareDx (CDNA), Amicus Therapeutics (FOLD) and Opko Health (OPK).

(APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.

Applied Therapeutics' lock-up period expired on Monday, November 11th. Applied Therapeutics had issued 4,000,000 shares in its initial public offering on May 14th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Applied Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (3.12%), Millennium Management LLC (0.15%), State Street Corp (0.06%), Emerald Advisers LLC (0.06%) and California State Teachers Retirement System (0.02%). Company insiders that own Applied Therapeutics stock include Joel S Marcus, Real Estate Equitie Alexandria and Shoshana Shendelman. View Institutional Ownership Trends for Applied Therapeutics.

APLT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Applied Therapeutics.

APLT stock was bought by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, State Street Corp, Emerald Advisers LLC and California State Teachers Retirement System. Company insiders that have bought Applied Therapeutics stock in the last two years include Joel S Marcus, Real Estate Equitie Alexandria and Shoshana Shendelman. View Insider Buying and Selling for Applied Therapeutics.

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APLT stock can currently be purchased for approximately $20.93.

Applied Therapeutics has a market capitalization of $358.61 million. Applied Therapeutics employs 4 workers across the globe.View Additional Information About Applied Therapeutics.

The official website for Applied Therapeutics is http://www.appliedtherapeutics.com/.

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]